Expanded Khorana risk score
. | Risk score . |
---|---|
Cancer type | |
Very high risk: brain, pancreatic, gastric | 2 |
High risk: lung, lymphoma, gynecologic, bladder, testicular, myeloma, kidney | 1 |
Hematological markers | |
Prechemotherapy platelet count ≥350 × 109/L | 1 |
Hemoglobin count <100 g/L or use of red cell growth factors | 1 |
Prechemotherapy leukocyte count >11 × 109/L | 1 |
Patient factor | |
Body mass index ≥35 kg/m2 | 1 |
Procoagulant markers | |
D-dimer ≥ 1.44 μg/mL | 1 |
Soluble P-selectin ≥ 53.1 ng/mL | 1 |
. | Risk score . |
---|---|
Cancer type | |
Very high risk: brain, pancreatic, gastric | 2 |
High risk: lung, lymphoma, gynecologic, bladder, testicular, myeloma, kidney | 1 |
Hematological markers | |
Prechemotherapy platelet count ≥350 × 109/L | 1 |
Hemoglobin count <100 g/L or use of red cell growth factors | 1 |
Prechemotherapy leukocyte count >11 × 109/L | 1 |
Patient factor | |
Body mass index ≥35 kg/m2 | 1 |
Procoagulant markers | |
D-dimer ≥ 1.44 μg/mL | 1 |
Soluble P-selectin ≥ 53.1 ng/mL | 1 |
Adapted from Ay et al.22